6 Top Gainers In Healthcare Sector (SOLY, PFNX, VRAY…)

(RTTNews) - The following are some of today's top gainers in the pharma/biotech sector.

1. Soliton Inc. (SOLY)

Soliton is a medical device company, which received FDA clearance to market its Rapid Acoustic Pulse ("RAP") device for tattoo removal in May of this year. The potential of the RAP device is also being explored to reduce cellulite and enhance existing fat removal technologies.

Gained 20.98% to close Monday's (Aug.12) trading at $10.90.

News: No news

Recent events:

-- On May 29, 2019, the Company announced positive results from its proof-of-concept trial of a new higher-powered version of Rapid Acoustic Pulse (RAP) device, with 20-47% improvement in cellulite severity score. This new higher-powered version of the RAP device is not yet approved by the FDA. -- On August 12, 2019, the Company announced that it has initiated patient recruitment for its upcoming pivotal cellulite trial evaluating the new higher-powered version of RAP device across all four trial sites.

2. China SXT Pharmaceuticals Inc. (SXTC)

China SXT Pharmaceuticals is a pharmaceutical company developing and marketing traditional Chinese medicine pieces, which is a type of Traditional Chinese Medicine that has been processed to be ready for use.

Gained 18.72% to close Monday's trading at $2.79.

News: No news

Recent events:

-- On March 28, 2019, the Company announced its financial results for the six months ended September 30, 2018.

Net income was $1.00 million, or $0.05 per share, for the six months ended September 30, 2018, compared to $0.79 million, or $0.04 per share, for the same period of the prior fiscal year. For the six months ended September 30, 2018, total revenues increased to $3.92 million from $3.89 million for the same period of the prior fiscal year.

-- On January 4, 2019, the Company went public on the NASDAQ Capital Market, offering its shares at a price of $4.00 per share.

3. Miragen Therapeutics Inc. (MGEN)

miRagen Therapeutics is a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs.

Gained 16.03% to close Monday's trading at $1.23.

News: No news

Near-term Catalysts:

-- Results from phase I clinical trials for MRG-110 that assessed safety, tolerability and proof of mechanism in humans are expected in the fourth quarter of 2019. MRG-110 is a potential treatment for chronic ischemic disorders. -- Interim data from phase II trial of Remlarsen in the prevention or reduction of keloid scarring are anticipated before the end of this year. -- A phase II study of Cobomarsen in cutaneous T-cell lymphoma, dubbed SOLAR, is underway, with primary endpoint data expected in the first half of 2021.

4. Pfenex Inc. (PFNX)

Pfenex is a clinical-stage development and licensing biotechnology company.

Gained 14.44% to close Monday's trading at $7.21.

News: No news

Near-term Catalyst:

-- The Company's 505(b)(2) New Drug Application for its lead product candidate PF708 is under FDA review - with a decision date set for October 7, 2019.

PF708 is being developed as a therapeutic equivalent candidate to Forteo, which is approved and marketed by Eli Lilly and Company for the treatment of osteoporosis in certain patients with a high risk of fracture. Forteo achieved $1.6 billion in global product sales in 2018.

5. AMAG Pharmaceuticals Inc. (AMAG)

AMAG is a revenue-generating pharmaceutical company.

Gained 14.19% to close Monday's trading at $11.83.

News: No news

Near-term Catalyst:

Vyleesi, a melanocortin receptor agonist that was approved by the FDA on June 21, 2019, to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women, is all set to be launched in the country in September.

6. ViewRay Inc. (VRAY)

ViewRay designs, manufactures and markets the MRIdian radiation therapy system.

Gained 11.94% to close Monday's trading at $3.47.

News: No news

Recent event:

On August 8, 2019, the Company reported financial results for the second quarter ended June 30, 2019.

Total revenue was $30.2 million in the recent second quarter, primarily from 5 revenue units, compared to $16.4 million, primarily from 3 revenue units, for the same period last year. Net loss was $30.8 million, or $0.32 per share, compared to $22.0 million, or $0.30 per share, for the same period last year.

Looking ahead, the Company expects 2019 annual revenue to be in the range of $80 million to $95 million. The annual revenue in 2018 was $81.0 million.